Progress in the treatment of bleeding disorders.
Bergman
Garrett E
GE
Medical Affairs, CSL Behring, King of Prussia, Pennsylvania, USA. Garrett.Bergman@cslbehring.com
D001778:Blood Coagulation Disorders / Q000188:drug therapy*; D003029:Coagulants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005164:Factor IX / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005169:Factor VIII / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D011788:Quality of Life; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D014842:von Willebrand Diseases / Q000188:drug therapy; D014841:von Willebrand Factor / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*
D003029:Coagulants; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D005169:Factor VIII; D005164:Factor IX